Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate

Benzinga · 2d ago
Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent.